Arjet Gega, MD
Infectious Disease · Waterbury, CTNPI 1487851317
Payments from drug & device makers
What this record shows
Gilead accounts for 68.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $1,430 and has fallen 71.0% since, to $415 in 2025.
Across 91 payments — averaging $35.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$396
- Merck$291
- AbbVie$169
- GSK$55
- Insmed, Inc.$52
- plus $53 from 2 others
What the payments were for
- Consulting fees$1,43045%
- Food & beverage$1,78055%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 42 | $2,194 |
| Viiv Healthcare Company | 17 | $396 |
| Merck | 16 | $291 |
| AbbVie | 7 | $169 |
| GSK | 3 | $55 |
| Insmed, Inc. | 3 | $52 |
| Melinta Therapeutics, LLC | 2 | $31 |
| Theratechnologies Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$1,430
How this compares
$3,210 in reported general payments places this provider in the 80th percentile of 159 infectious disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 72 | $362,172 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 31 | $117,285 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $94,600 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $60,003 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 17 | $13,608 |
| Vancomycin Hcl | 11 | $3,181 |
| Methenamine Hippurate | 20 | $1,583 |
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 19 | $820 |
| Azithromycin | 31 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $2,194 | $422,17585 claims |
| Viiv Healthcare CompanyTriumeq, Cabenuva | $396 | $211,88444 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 159 infectious disease providers in Connecticut.
Other infectious disease in Waterbury
- Raphael ShawWaterbury$3K
- Samuel PanWaterbury$2K
- Fahmida McGannWaterbury$2K
- Bethel ShiferawWaterbury$763
- Marinela IngilizovaWaterbury$519
- Zane SaulStratford$513K
- Stephen ScholandMeriden$428K
- Onyema OgbuaguNew Haven$412K
- David RubinNorwalk$397K
- Steven SchnittmanWest Haven$363K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.